Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 36.4 %

Shares of EGRX stock opened at $0.75 on Friday. The business’s fifty day moving average price is $0.73 and its 200 day moving average price is $3.17. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several hedge funds have recently bought and sold shares of EGRX. Vanguard Group Inc. increased its position in shares of Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after buying an additional 2,630 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Eagle Pharmaceuticals during the 1st quarter valued at about $83,000. AIGH Capital Management LLC raised its position in Eagle Pharmaceuticals by 2.1% during the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after acquiring an additional 25,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $76,000. Finally, XTX Topco Ltd acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $113,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.